

## Brilliant Violet 510™ anti-human CD19 Antibody

<b>Catalog# / Size</b>	302241 / 25 tests 302242 / 100 tests
<b>Clone</b>	HIB19
<b>Regulatory Status</b>	RUO
<b>Workshop</b>	V CD19.11
<b>Other Names</b>	B4
<b>Isotype</b>	Mouse IgG1, κ
<b>Description</b>	CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

### Product Details

---

<b>Verified Reactivity</b>	Human
<b>Reported Reactivity</b>	Chimpanzee
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
<b>Concentration</b>	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.</p> <p>Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. <b>Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.</b> Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.</p> <p><a href="#">Learn more about Brilliant Violet™.</a></p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
<b>Excitation Laser</b>	Violet Laser (405 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections <sup>8</sup> and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody

(Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

Clone H1B19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

## Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, *et al.* 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
3. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.
4. Joseph A, *et al.* 2010. *J. Virol.* 84:6645. [PubMed](#)
5. Wang X, *et al.* 2010. *Haematologica.* 95:884. (FC) [PubMed](#)
6. Walker JD, *et al.* 2009. *J. Immunol.* 182:1548. (Block) [PubMed](#)
7. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
8. Hansen A, *et al.* 2002. *Arthritis Rheum.* 46:2160. (IHC)
9. Stoeckius M, *et al.* 2017. *Nat. Methods.* 14:865. (PG)
10. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)

## Product Citations

1. Sannier G, *et al.* 2021. *Cell Reports.* 36(9):109643. [PubMed](#)
2. Eslamizar L, *et al.* 2021. *NPJ Vaccines.* 6:15. [PubMed](#)
3. Krummey SM, *et al.* 2020. *Cell Reports.* 30(5):1282-1291.e5.. [PubMed](#)
4. Lagou V *et al.* 2018. *Cell reports.* 25(3):798-810 . [PubMed](#)
5. Li C, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
6. Martrus G, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0182532. [PubMed](#)
7. Schlicher L, *et al.* 2022. *Int J Mol Sci.* 23:. [PubMed](#)
8. Groß R, *et al.* 2022. *EBioMedicine.* 75:103761. [PubMed](#)
9. Kokkinopoulos I, *et al.* 2021. *Sci Rep.* 11:15759. [PubMed](#)
10. Chen M, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
11. Weisberg SP, *et al.* 2020. *Cell Reports.* 29(12):3916-3932.e5.. [PubMed](#)
12. Catapano M, *et al.* 2020. *J Invest Dermatol.* 140:816. [PubMed](#)
13. Romero-Olmedo AJ, *et al.* 2022. *Nat Microbiol.* 7:195. [PubMed](#)
14. Demers K, *et al.* 2016. *PLoS Pathog.* 12: 1005805. [PubMed](#)
15. Pape KA, *et al.* 2021. *Cell Rep.* 37:109823. [PubMed](#)
16. Kuri-Cervantes L, *et al.* 2020. *STAR Protoc.* 1:100154. [PubMed](#)
17. Hu EY, *et al.* 2021. *Blood Adv.* 5:3152. [PubMed](#)
18. van der Ploeg K, *et al.* 2022. *Cell Rep Med.* 3:100640. [PubMed](#)
19. Caduff N, *et al.* 2021. *Cell Reports.* 35(5):109056. [PubMed](#)
20. Yarmarkovich M, *et al.* 2021. *Nature.* 599:477. [PubMed](#)
21. Bonifacius A, *et al.* 2021. *Immunity.* 54(2):340-354.e6. [PubMed](#)
22. Bäcker-Koduah P, *et al.* 2020. *Ann Clin Transl Neurol.* 1.422222222. [PubMed](#)
23. Rutishauser L, *et al.* 2017. *AIDS Res Hum Retroviruses .* 10.1089/AID.2016.0324. [PubMed](#)
24. Silver J, *et al.* 2020. *Methods Mol Biol.* 2121:115. [PubMed](#)
25. Hu EY, *et al.* 2020. *JCI Insight.* 5:00. [PubMed](#)
26. Buggert M, *et al.* 2020. *Cell.* 183(7):1946-1961.e15. [PubMed](#)
27. Tong P, *et al.* 2021. *Cell.* :. [PubMed](#)
28. Bradley T *et al.* 2018. *Cell.* 175(2):387-399 . [PubMed](#)
29. Pape KA, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
30. Morris AB, *et al.* 2020. *Immunity.* 52(1):136-150.e6.. [PubMed](#)
31. Pucino V, *et al.* 2020. *Cell Metabolism.* 30(6):1055-1074.e8.. [PubMed](#)
32. Shih T, *et al.* 2019. *Front Immunol.* 10:1652. [PubMed](#)
33. Gao Y, *et al.* 2022. *Immunity.* 55:1732. [PubMed](#)
34. Peluso MJ, *et al.* 2021. *Cell Rep.* 36:109518. [PubMed](#)
35. Cohen CA, *et al.* 2021. *Nat Commun.* 12:4678. [PubMed](#)
36. Rakshit S, *et al.* 2020. *Cell Rep.* 33:108451. [PubMed](#)
37. Moguche AO *et al.* 2017. *Cell host & microbe.* 21(6):695-706 . [PubMed](#)
38. Mudd PA, *et al.* 2022. *Cell.* 185:603. [PubMed](#)
39. Sekine T, *et al.* 2020. *Cell.* 183:158. [PubMed](#)
40. Sagebiel AF, *et al.* 2019. *Nat Commun.* 10:975. [PubMed](#)
41. Ruella M, *et al.* 2018. *Nat Med.* 24:1499. [PubMed](#)
42. NULL, *et al.* 2022. *Cell.* 185:916. [PubMed](#)
43. Chen Y, *et al.* 2020. *Cell.* 1496:183. [PubMed](#)
44. Danzer H, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
45. Baxter AE, *et al.* 2017. *Nat Protoc.* 12:2029. [PubMed](#)
46. Mackroth M, *et al.* 2016. *PLoS Pathog.* 12:e1005909. [PubMed](#)
47. Sung JA, *et al.* 2018. *Mol Ther.* 26:2496. [PubMed](#)
48. Abd Hamid M *et al.* 2019. *Cancer Immunol Res.* 7(8):1293-1306 . [PubMed](#)
49. Giron LB, *et al.* 2020. *EBioMedicine.* 73.94791667. [PubMed](#)
50. Vanderbeke L, *et al.* 2021. *Nat Commun.* 12:4117. [PubMed](#)
51. Upasani V, *et al.* 2019. *Front Immunol.* 2.152777778. [PubMed](#)
52. Gamradt S, *et al.* 2021. *iScience.* 24:103312. [PubMed](#)

## RRID

AB\_2561381 (BioLegend Cat. No. 302241)  
AB\_2561668 (BioLegend Cat. No. 302242)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, type I transmembrane glycoprotein, 95 kD
<b>Distribution</b>	B lineage (except plasma cells), follicular dendritic cells
<b>Function</b>	B cell activation and differentiation
<b>Ligand/Receptor</b>	Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
<b>Cell Type</b>	B cells, Dendritic cells
<b>Biology Area</b>	Costimulatory Molecules, Immunology
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	1. Tedder T, <i>et al.</i> 1994. <i>Immunol. Today</i> 15:437. 2. Bradbury L, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2915.
<b>Gene ID</b>	<a href="#">930</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-human CD19, Biotin anti-human CD19, FITC anti-human CD19, PE anti-human CD19, PE/Cyanine5 anti-human CD19, Purified anti-human CD19, APC/Cyanine7 anti-human CD19, PE/Cyanine7 anti-human CD19, Alexa Fluor® 488 anti-human CD19, Alexa Fluor® 647 anti-human CD19, Pacific Blue™ anti-human CD19, Alexa Fluor® 700 anti-human CD19, PerCP anti-human CD19, PerCP/Cyanine5.5 anti-human CD19, Brilliant Violet 421™ anti-human CD19, Brilliant Violet 570™ anti-human CD19, Brilliant Violet 650™ anti-human CD19, Brilliant Violet 785™ anti-human CD19, Brilliant Violet 510™ anti-human CD19, Brilliant Violet 605™ anti-human CD19, Brilliant Violet 711™ anti-human CD19, Purified anti-human CD19 (Maxpar® Ready), Alexa Fluor® 594 anti-human CD19, PE/Dazzle™ 594 anti-human CD19, APC/Fire™ 750 anti-human CD19, TotalSeq™-A0050 anti-human CD19, Brilliant Violet 750™ anti-human CD19, TotalSeq™-B0050 anti-human CD19, TotalSeq™-C0050 anti-human CD19, Spark NIR™ 685 anti-human CD19, Ultra-LEAF™ Purified anti-human CD19, APC/Fire™ 810 anti-human CD19, PE/Fire™ 640 anti-human CD19, PE/Fire™ 700 anti-human CD19, TotalSeq™-D0050 anti-human CD19, Spark YG™ 593 anti-human CD19, GMP Pacific Blue™ anti-human CD19, Spark Violet™ 423 anti-human CD19, GMP PE anti-human CD19, GMP APC anti-human CD19, KIRAVIA Blue 520™ anti-human CD19, GMP PerCP/Cyanine5.5 anti-human CD19, GMP PE/Cyanine7 anti-human CD19, Spark Violet™ 500 anti-human CD19

## Product Data



Human peripheral blood lymphocytes were stained with CD3 APC and CD19 (clone HIB19) Brilliant Violet 510™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

